Crinetics Pharmaceuticals, Inc.
CRNX
$36.05
-$1.84-4.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.16M | 143.00K | 1.03M | 361.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.16M | 143.00K | 1.03M | 361.00K | 0.00 |
| Cost of Revenue | 86.13M | 90.46M | 13.10M | 76.24M | 66.57M |
| Gross Profit | -79.97M | -90.32M | -12.07M | -75.88M | -66.57M |
| SG&A Expenses | 53.70M | 52.27M | 49.84M | 35.53M | 28.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 139.83M | 142.73M | 130.14M | 111.77M | 94.75M |
| Operating Income | -133.67M | -142.59M | -129.11M | -111.41M | -94.75M |
| Income Before Tax | -122.64M | -130.09M | -115.64M | -96.77M | -80.60M |
| Income Tax Expenses | 180.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.82M | -130.09M | -115.64M | -96.77M | -80.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.82M | -130.09M | -115.64M | -96.77M | -80.60M |
| EBIT | -133.67M | -142.59M | -129.11M | -111.41M | -94.75M |
| EBITDA | -132.67M | -141.57M | -128.15M | -110.48M | -93.96M |
| EPS Basic | -1.29 | -1.38 | -1.23 | -1.04 | -0.88 |
| Normalized Basic EPS | -0.81 | -0.86 | -0.77 | -0.65 | -0.55 |
| EPS Diluted | -1.29 | -1.38 | -1.23 | -1.04 | -0.88 |
| Normalized Diluted EPS | -0.81 | -0.86 | -0.77 | -0.65 | -0.55 |
| Average Basic Shares Outstanding | 95.10M | 94.22M | 93.79M | 93.10M | 91.49M |
| Average Diluted Shares Outstanding | 95.10M | 94.22M | 93.79M | 93.10M | 91.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |